| __timestamp | CRISPR Therapeutics AG | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 15823000 |
| Thursday, January 1, 2015 | 12573000 | 17026000 |
| Friday, January 1, 2016 | 42238000 | 15941000 |
| Sunday, January 1, 2017 | 69800000 | 18938000 |
| Monday, January 1, 2018 | 113773000 | 58124000 |
| Tuesday, January 1, 2019 | 179362000 | 83837000 |
| Wednesday, January 1, 2020 | 266946000 | 35882000 |
| Friday, January 1, 2021 | 438633000 | 64542000 |
| Saturday, January 1, 2022 | 461645000 | 67995000 |
| Sunday, January 1, 2023 | 387332000 | 80118000 |
| Monday, January 1, 2024 | 320653000 |
Igniting the spark of knowledge
In the rapidly evolving biotech industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, CRISPR Therapeutics AG and CymaBay Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. From 2014 to 2023, CRISPR Therapeutics AG increased its R&D expenses by an impressive 25,500%, peaking in 2022. This surge underscores their aggressive pursuit of cutting-edge gene-editing technologies. In contrast, CymaBay Therapeutics, Inc. exhibited a more modest growth of 406% in the same period, reflecting a steady yet cautious approach to innovation. Notably, CRISPR's R&D spending in 2023 was nearly five times that of CymaBay, highlighting their dominant position in the biotech landscape. As these companies continue to innovate, their R&D investments will be crucial in shaping the future of medical breakthroughs.
Comparing Innovation Spending: Sanofi and CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs CymaBay Therapeutics, Inc.
Research and Development Investment: Ultragenyx Pharmaceutical Inc. vs CRISPR Therapeutics AG
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Analyzing R&D Budgets: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.
Viking Therapeutics, Inc. or CRISPR Therapeutics AG: Who Invests More in Innovation?
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.